LCM
VYNE icon

Lynx1 Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Lynx1 Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$973K Buy
+1,628,700
New +$950K 0.15% 17
2024
Q4 		– Sell
-16,194
Closed -$30.4K – 23
2024
Q3 		$30.4K Hold
16,194
– – 0.01% 18
2024
Q2 		$31.9K Buy
+16,194
New +$40.4K 0.01% 17

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lynx1 Capital Management's VYNE Position: Q1 2026 in Review

Lynx1 Capital Management opened a new position in VYNE Therapeutics (VYNE) in Q1 2026: 1,628,700 shares worth $973K. The stake represents 0.15% of the portfolio and ranks #17 among its holdings. This is a return to the name: Lynx1 Capital Management previously reported a position in VYNE as recently as Q3 2024.

Lynx1 Capital Management first reported a position in VYNE in Q2 2024 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • Lynx1 Capital Management held 1,628,700 shares of VYNE Therapeutics worth $973K as of Q1 2026.
  • VYNE Therapeutics was a new Lynx1 Capital Management position in Q1 2026.
  • VYNE Therapeutics made up 0.15% of Lynx1 Capital Management's portfolio in Q1 2026, its #17 holding.
  • Lynx1 Capital Management first reported a position in VYNE Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Lynx1 Capital Management's 13F filing for Q1 2026, filed 4 May 2026.